Grandaxin

Grandaxin is a prescription tablet containing 50 mg of tofisopam, a benzodiazepine‑derivative anxiolytic marketed in the European Union. It is formulated for oral administration and is classified as an unscheduled prescription medication. Tofisopam acts as a positive allosteric modulator of the GABA‑A receptor, providing anxiety relief without marked sedation or muscle relaxation. The tablet is intended for management of generalized anxiety symptoms and is prescribed by physicians after evaluating patient needs.

Grandaxin (tofisopam 50 mg tablets) is primarily indicated for the symptomatic treatment of anxiety disorders in adult patients.

- Short‑term relief of generalized anxiety symptoms. - Adjunctive therapy for anxiety associated with depressive disorders. - Management of situational anxiety such as performance or test anxiety. - Use in patients who require anxiolysis without pronounced sedation. - Consideration as an alternative when conventional benzodiazepines cause excessive muscle relaxation. - Short‑duration prescribing to minimize risk of dependence. - May be selected for patients with a history of sedation‑related adverse effects from other anxiolytics.

The safety profile of Grandaxin reflects its benzodiazepine‑derivative structure, with most adverse events being mild and reversible.

Common: - Drowsiness or mild fatigue. - Headache. - Nausea or gastrointestinal discomfort. - Dizziness. - Dry mouth or mild xerostomia. - Transient visual disturbances such as blurred vision. - Insomnia or difficulty sleeping. - Weight gain or appetite changes.

Serious: - Severe allergic reaction (rash, swelling, difficulty breathing). - Mood changes such as depression or suicidal thoughts. - Paradoxical agitation or aggression. - Respiratory depression when combined with other central depressants. - Hepatic enzyme elevation indicating possible liver stress. - Seizure threshold reduction in predisposed individuals. - Cardiovascular effects such as tachycardia or hypotension. - Withdrawal symptoms on abrupt discontinuation after prolonged use.

When prescribing Grandaxin, clinicians should evaluate patient history and monitor for conditions that could increase risk of adverse outcomes.

- Assess for a history of substance misuse or dependence. - Use caution in patients with hepatic or renal impairment; dose adjustment may be required. - Avoid use during pregnancy or lactation unless benefits clearly outweigh risks. - Monitor elderly patients closely due to increased sensitivity to sedative effects. - Evaluate for concurrent depressive disorders or suicidal ideation before initiating therapy. - Do not combine with other central nervous system depressants without medical supervision.

Grandaxin may interact with other medications that influence the central nervous system or hepatic metabolism, potentially altering its efficacy or safety.

Avoid: - Concomitant use with other benzodiazepines or barbiturates. - Strong CYP3A4 inhibitors such as ketoconazole or clarithromycin. - Opioid analgesics without close medical supervision. - Grapefruit juice, which can increase plasma concentrations of tofisopam.

Use with caution: - Alcohol consumption, which can enhance sedative effects. - Antidepressants, particularly SSRIs, that may increase serotonergic activity. - Antihistamines or antipsychotics that also depress CNS function. - Herbal supplements like St. John’s wort that induce hepatic enzymes. - CNS‑active antihypertensives that may cause additive hypotensive effects. - Anticonvulsants that are strong enzyme inducers, such as carbamazepine, which may reduce tofisopam levels.